197178-54-4

Upstream product

• 7311-34-4 3,5-dimethoxybenzaldehdye 

Downstream Products

• 74356-41-5 5-(3,5-dihydroxyphenyl)pentanoic acid 
• 53413-28-8 5''-OH-cannabidiol 
• 63998-82-3 (3R,4R)-ω-carboxy-p-cannabidiol 
• 120467-25-6 (3R,4R)-ω-carboxy-o-cannabidiol 
• 197178-44-2 (1R,4R,5S)-4-[2-methoxy-6-hydroxy-4-(5-tert-butyldimethylsilyloxypentyl)phenyl]-6,6-dimethylbicyclo[3.1.1]heptan-2-one 
• 197178-43-1 (1R,4R,5S)-4-[2,6-dimethoxy-4-(5-tert-butyldimethylsilyloxypentyl)phenyl]-6,6-dimethylbicyclo[3.1.1]heptan-2-one 
• 197178-42-0 (1R,5S)-(-)-4-[2,6-dimethoxy-4-(5-tert-butyldimethylsilyloxypentyl)phenyl]-6,6-dimethylbicyclo[3.1.1]hept-3-en-2-one 
• 197178-41-9 1-(tert-butyldimethylsilyloxy)-5-(3,5-dimethoxyphenyl)pentane 
• 1972-08-3 dronabinol 
• 886-52-2 5-(5'-bromopentyl)-1,3-dimethoxybenzene 
• 58545-34-9 1-(5-bromopentyl)benzene-1,3-diol 
• 836-27-1 1,3-dimethoxy-5-(5-hydroxypentyl)benzene 

Relevant academic research and scientific papers

Discovery of KLS-13019, a Cannabidiol-Derived Neuroprotective Agent, with Improved Potency, Safety, and Permeability

Cannabidiol is the nonpsychoactive natural component of C. sativa that has been shown to be neuroprotective in multiple animal models. Our interest is to advance a therapeutic candidate for the orphan indication hepatic encephalopathy (HE). HE is a serious neurological disorder that occurs in patients with cirrhosis or liver failure. Although cannabidiol is effective in models of HE, it has limitations in terms of safety and oral bioavailability. Herein, we describe a series of side chain modified resorcinols that were designed for greater hydrophilicity and "drug likeness", while varying hydrogen bond donors, acceptors, architecture, basicity, neutrality, acidity, and polar surface area within the pendent group. Our primary screen evaluated the ability of the test agents to prevent damage to hippocampal neurons induced by ammonium acetate and ethanol at clinically relevant concentrations. Notably, KLS-13019 was 50-fold more potent and >400-fold safer than cannabidiol and exhibited an in vitro profile consistent with improved oral bioavailability.

Δ9-tetrahydrocannabinol immunochemical studies: Haptens, monoclonal antibodies, and a convenient synthesis of radiolabeled Δ9-tetrahydrocannabinol

Immunopharmacotherapy as an approach to combat drugs of abuse has become an active area of investigation. Marijuana is the most commonly used illicit drug in the U.S. The main active chemical in marijuana is Δ9- tetrahydrocannabinol (Δ9-THC); hence, monoclonal antibodies with high affinity and specificity for Δ9-tetrahydrocannabinol could be valuable immunopharmacotherapeutic intervention and diagnostic tools. We have synthesized immunoconjugates that induce an effective immune response to Δ9-THC and describe a convenient synthesis of radiolabeled Δ9-THC. We demonstrate the value and use of this probe to select anti-Δ9-THC antibodies that bind Δ9-THC with good affinity. The synthetic route to radiolabeled Δ9-THC has enabled the correct assessment of the affinity of these antibodies to their ligand and may facilitate future binding studies between Δ9- THC and its analogues and the cannabinoid receptors.

Synthesis of 5',11-dihydroxy-Δ8-tetrahydrocannabinol

The synthesis of a polar cannabinoid, 5',11-dihydroxy-Δ8-tetrahydrocannabinol (2), has been carried out. A key step in the synthesis is the reaction of an aryllithium derived from 1-(tert-butyldimethylsilyloxy)-5-(3,5-dimethoxyphenyl) pentane w